Multiple Sclerosis Supplements: What the Trials Actually Show
Multiple sclerosis affects about 2.8 million people worldwide. The mean age at diagnosis is 32, and females are twice as likely to be affected as males [1]. This guide covers what the human trials actually show, the doses that were used, and the line no supplement crosses.
What Supplements Can and Cannot Do in MS
MS is an immune-mediated disease of the central nervous system. It damages myelin, the sheath around nerve fibers, and that damage can disturb movement, sensation, vision, and energy. No supplement changes that underlying course. None of the products here treats, slows, cures, or prevents MS.
Supplements can do something narrower. They can correct a measured deficiency, support normal nerve function, support normal immune function, and support energy metabolism. That is structure and function support, not disease modification.
Disease-modifying therapy is the backbone of MS care. Every trial below tested a supplement alongside standard care, or in people who were not yet on therapy. None replaced it.
A 2018 review in JAMA Neurology concluded that vitamin D is the only vitamin with enough evidence to support routine supplementation in MS, and the goal is avoiding deficiency [2]. Treat the deficiency, not the diagnosis.
For general nerve support, see our guide to nutrients that support normal nerve function. If cognition is part of your picture, the brain and memory resource page covers nutrients studied for cognitive support.
The useful question is not "which supplement treats MS." It is "which deficiency do I have, and what does the evidence say about correcting it?"
Vitamin D: The Strongest Case, and the Trials That Disagree
Vitamin D gets more attention in MS than any other nutrient. The observational case is strong, and the randomized case is mixed. The newest trial changed the conversation without settling it.
The association data
Researchers measure vitamin D status as 25-hydroxyvitamin D, or 25(OH)D. In observational studies, each 25 nmol/L increase is associated with 14% to 34% lower relapse risk and 15% to 50% lower risk of new MRI lesions [3]. These are associations, not proof of cause and effect.
People with more active disease may also spend less time outdoors. Association is a clue worth testing, not a verdict.
The four randomized trials
- SOLAR. 14,000 IU of vitamin D3 daily versus placebo for 48 weeks in 232 people, all on interferon beta-1a. The primary endpoint, NEDA-3 at 48 weeks, was not met. Secondary analyses showed fewer new or enlarging lesions and fewer new T2 lesions [3].
- CHOLINE. 100,000 IU every other week versus placebo for 96 weeks in 129 people, all on interferon beta-1a. The primary endpoint, annualized relapse rate, was not met. Secondary signals appeared in the 90 people who completed the study [3].
- PrevANZ. 1,000, 5,000, or 10,000 IU daily versus placebo for up to 48 weeks in 204 enrolled and 199 analyzed. There was no reduction in conversion to MS, with hazard ratios of 0.87, 1.37, and 1.28, and the trial reported it as well tolerated [4].
- D-Lay MS. 100,000 IU of cholecalciferol every 2 weeks versus placebo for 24 months in 316 people with untreated clinically isolated syndrome. The composite disease activity outcome occurred in 60.3% versus 74.1% (HR 0.66, 95% CI 0.50 to 0.87, P = .004). MRI activity, new lesions, and contrast-enhancing lesions all favored vitamin D [5].
D-Lay MS was not a relapse reduction. The relapse difference was not statistically significant: 17.9% versus 21.8% (HR 0.69, 95% CI 0.42 to 1.16) [5]. Do not read that trial as proof that vitamin D prevents relapses.
Why the trials disagree
Four differences explain most of the gap.
- The people. PrevANZ and D-Lay MS enrolled people with clinically isolated syndrome. SOLAR and CHOLINE enrolled people with established disease.
- The background therapy. SOLAR and CHOLINE required interferon beta-1a. D-Lay MS enrolled untreated people.
- The dose and schedule. SOLAR used 14,000 IU daily. CHOLINE and D-Lay MS used large intermittent doses.
- The endpoint. NEDA-3, annualized relapse rate, conversion to MS, and a composite score are not the same outcome.
A null primary endpoint does not erase a positive secondary, and a positive composite does not prove relapse prevention. The honest summary is that vitamin D looks most useful when a person is deficient.
A practical testing and dosing approach
Start with a blood test. Ask for 25(OH)D and ask for the number, not just the word "normal."
The 2011 Institute of Medicine report sets the adult recommended dietary allowance at 600 IU for ages 19 to 70 and 800 IU for ages 71 and older. It sets the tolerable upper intake level at 4,000 IU per day for adults [6]. The 4,000 IU figure is a safety ceiling for unsupervised daily use, not a treatment target.
The trial doses above went higher, and some used intermittent high doses. Those were clinician-supervised protocols. Do not copy 100,000 IU at home.
The 2024 Endocrine Society guideline suggests against empiric vitamin D above the dietary reference intake in healthy adults younger than 75. It also suggests daily rather than high-dose intermittent dosing for people over 50, because high-dose intermittent dosing may increase falls [7][20].
A reasonable approach looks like this:
- Test 25(OH)D before you start.
- If you are low, ask your clinician for a correction plan and a retest date.
- For maintenance, stay within the 4,000 IU daily upper limit unless a clinician directs otherwise.
- Avoid self-prescribed high-dose intermittent dosing, especially if you are over 50 or at risk of falls.
For forms and cofactors, our vitamin D3 and K2 guide explains what to look for on a label.
Lipoic Acid: The Strongest Mechanistic Story and the Disappointing Phase 2
Lipoic acid is an antioxidant the body makes in small amounts. It helps regenerate other antioxidants and supports normal nerve function. Mechanism is not evidence, and the clinical story is more modest than the marketing.
The early signals
Two small trials kept interest alive. In one, 1,200 mg daily for 12 weeks in 24 people with relapsing-remitting MS, EDSS did not increase in the supplement group [8]. In another, 1,200 mg daily for 12 weeks in 52 people with relapsing-remitting MS, several cytokines changed, but EDSS, TNF-alpha, and IL-6 did not [9].
Both studies were small and short. A stable EDSS in a few dozen people is a signal worth testing, not a reason to expect a benefit.
The 2026 phase 2 trial
The larger trial gave 1,200 mg of lipoic acid daily or placebo for 24 months to 115 people with progressive MS across 10 US sites and 1 Canadian site [10].
The primary walking result was null. Walking speed changed by -0.39 feet per second in the lipoic acid group and -0.30 feet per second in the placebo group, with no meaningful difference [10].
Some imaging findings leaned the other way. Whole-brain volume seemed stable in the lipoic acid group while placebo trended down. Deep gray matter stayed stable in the lipoic acid group and decreased in the placebo group [10].
Those are hypothesis-generating signals, not proof of protection.
Safety and tolerability were the practical problem. The lipoic acid group had more proteinuria. Discontinuation was 37% versus 17%, and the trial was rated Class II evidence [10].
The 2026 trial did not show that lipoic acid protects nerves. It showed a null walking result and an imaging signal worth following.
The tolerability finding that matters
A crossover trial compared 600 mg of R-lipoic acid with 1,200 mg of the racemic R,S form. The 600 mg R dose was bioequivalent to the 1,200 mg racemic dose and produced fewer gastrointestinal side effects: 31 reports versus 60, P = .025 [11].
That matters because the trial dose is large and the dropout rate was high. If you and your clinician decide to try lipoic acid, the tolerability data favor 600 mg of R-lipoic acid over 1,200 mg of the racemic form. It does not erase the null walking result or the proteinuria signal.
High-Dose Biotin: The Cautionary Tale
High-dose biotin is the clearest example of a signal that outran the evidence. Early reports suggested better walking. The pooled analysis told a narrower story.
A 2021 meta-analysis pooled 3 randomized trials with 889 participants. All used at least 300 mg of biotin per day for at least 3 months [12].
The results split three ways:
- No significant difference in EDSS change. The disability score did not improve.
- A walking signal. In people with progressive MS, the 25-foot walk time favored biotin (RR 2.06, 95% CI 1.04 to 4.09), with moderate certainty.
- A safety problem. Lab test interference occurred in 4.7% versus 0%, with high certainty [12].
That last number is the one to remember. Biotin can distort common immunoassays, the lab tests used for thyroid and other hormones. A distorted result can lead to a wrong diagnosis or a wrong dose of another medicine.
If you take high-dose biotin, tell every clinician and every lab that draws your blood. Ask how long to stop before a test.
A walk-time signal with no EDSS benefit and a real lab-interference risk is not a treatment. It is a reason for caution.
Omega-3: Modest Biology, No Disability Benefit
Omega-3 fats support normal inflammatory balance and are part of a healthy diet. In MS, that biology has not translated into a disability benefit.
A 2019 meta-analysis pooled 4 trials. It found no significant effect on EDSS (WMD -0.07, 95% CI -0.27 to 0.13). It found no effect on IL-1beta or IL-6, and a significant reduction in TNF-alpha [13].
That pattern is common in nutrition research. A marker moves, and the clinical score does not. A lower TNF-alpha is a real biological signal, but it is not the same as walking better or feeling better.
Omega-3 is still reasonable for general health, especially if your diet is low in fatty fish. Our omega-3 benefits guide covers forms, dosing, and quality. Do not expect it to change MS disability, because the pooled data do not show that.
CoQ10, Magnesium, and B12: Deficiency First
Three more nutrients come up often. Each is best approached through testing and deficiency correction rather than routine high-dose use.
CoQ10
CoQ10 supports energy metabolism in cells. A 2025 systematic review found 8 reports from 6 studies (3 randomized, 2 semi-experimental, 1 retrospective) with a total of 195 participants.
The 200 mg daily results were controversial. The 500 mg daily results improved oxidative stress, inflammation, depression, and fatigue in small studies [14].
One open-label crossover study gave CoQ10 to 60 people for 3 months. It reported improved scavenging activity, reduced oxidative DNA damage, and lower EDSS, fatigue, depression, and pain scores [15].
That is encouraging, but the design is weak. There was no placebo group, the study was short, and the sample was small.
CoQ10 at 500 mg daily has a plausible signal and thin proof. Our CoQ10 benefits guide explains forms and absorption.
Magnesium
Magnesium supports normal muscle and nerve function. The MS-specific evidence is weaker than the marketing suggests.
A large cohort study found no association between baseline or cumulative mineral intake and MS risk [16]. That is about risk, not symptoms. For symptoms, a systematic review found sparse evidence on diet and MS-related fatigue, with a possible trend toward lower fatigue when magnesium and folate intake were adequate [17].
Deficiency comes first. Assess your intake and, if needed, your blood level.
If you supplement, choose a form that suits your digestion. Our guide to the types of magnesium supplements compares oxide, citrate, glycinate, and others.
Vitamin B12
B12 deficiency can cause fatigue and nerve symptoms that overlap with MS. That overlap is exactly why testing matters. A low B12 is treatable, and correcting it can improve how you feel.
There is no randomized evidence in this set that B12 changes MS course. Test first, then treat the deficiency, rather than taking a high dose on a guess.
Fatigue: What Actually Helps
Fatigue is one of the most common symptoms in MS. A 2024 meta-analysis pooled 69 studies from 27 countries and found a prevalence of 59.1% [18]. A separate systematic review reported a range of 36.5% to 78.0%, along with a consistent link to lower quality of life [19].
That prevalence explains why so many people search for MS fatigue supplements. It also explains why the market responds with so many products. The evidence does not keep up.
What has better support is not a capsule:
- Exercise. Supervised aerobic and resistance training is one of the best-supported approaches to MS fatigue.
- Sleep. Address sleep problems, and ask your clinician whether sleep apnea screening is appropriate.
- Depression. Treating depression may also help fatigue.
- Cognitive behavioral therapy. Cognitive behavioral therapy has evidence for MS fatigue in some trials.
Supplements come after those basics. CoQ10 has a small signal [14][15]. Adequate magnesium and folate intake has a possible trend [17].
Nothing in this set is strong enough to promise a meaningful energy lift. Fatigue is the symptom most likely to send people to the supplement aisle and the one where supplements have the least to offer.
What to Avoid or Handle Carefully
Some products are a waste of money. A few are a genuine risk.
- Anything marketed as an MS cure. A product that claims to cure, reverse, or stop MS is making a claim no supplement can support.
- Immune-stimulating botanicals. Echinacea, astragalus, and high-dose mushroom extracts are sometimes promoted for immune support. In an autoimmune disease, stimulating the immune system is a theoretical concern. Ask your neurologist.
- High-dose biotin before blood tests. Lab interference occurred in 4.7% versus 0% in the pooled trials [12]. Tell your clinicians and the lab.
- St John's wort with medications. It can change how the body handles some drugs and can lower blood levels of medicines. Check with your neurologist or pharmacist before combining it with MS therapy.
- High-dose intermittent vitamin D. The 2024 Endocrine Society guideline notes that high-dose intermittent dosing may increase falls [7]. Do not self-prescribe large occasional doses.
- Unregulated products with hidden ingredients. Imported creams, capsules, and powders sometimes contain drugs that are not on the label. Buy from a retailer that can show third-party testing.
A useful rule: if a product promises to replace your DMT, it is either uninformed or dishonest. The safe role for a supplement is support, not substitution.
How to Choose a Product Worth Buying
Once you know which nutrient you need, the product still has to be worth taking. Four checks do most of the work.
- Third-party testing. Look for a seal or certificate from an independent lab. Testing confirms that the label matches the contents and that heavy metals and microbes are controlled.
- Dose that matches the trial. If the studied dose was 500 mg of CoQ10 or 600 mg of R-lipoic acid, the product should let you take that dose without guesswork. A label that hides the dose behind a blend is a warning.
- Capsule count. A 1,200 mg racemic lipoic acid dose can mean two or three large capsules a day. A 600 mg R-lipoic acid product may need fewer.
- Cost per month. Compare the monthly cost at the studied dose, not the sticker price per bottle.
Read the supplement facts panel closely. Our guide on how to read a supplement label walks through serving size, elemental weight, and filler ingredients. A product that is transparent about all three is usually the better buy.
What We Recommend
The Agape team stocks practitioner-grade options for the nutrients with the clearest testing and dosing story.
Integrative Therapeutics, Pure Omega Ultra HP 90 Softgels
1,085 mg of omega-3 per softgel (575 mg EPA and 425 mg DHA), third-party tested for purity and labeled potency.
$69.25
DaVinci Labs, D3/K2 Liquid 75 Servings
2,000 IU of vitamin D3 with 200 mcg of K2 per two-spray serving, half the 4,000 IU adult daily upper limit, with a clinician check first if you take a blood thinner.
$76.34
Integrative Therapeutics, Magnesium Glycinate Plus 120 Tablets
220 mg of magnesium as glycinate, lysinate, and aspartate per two-tablet serving, a chelated form chosen for tolerance.
$29.25
DaVinci Labs, Alpha Lipoic Acid 300 - 60 Capsules
300 mg of alpha-lipoic acid per capsule, so matching the 1,200 mg daily trial dose takes four capsules a day.
$31.30
Frequently Asked Questions
What are the best supplements for MS?
There is no single best supplement, because no supplement changes the course of MS. The most defensible choices correct a measured deficiency. Vitamin D has the strongest case for routine use when a level is low [2]. CoQ10, magnesium, and B12 are reasonable only when intake or a lab result supports them.
Does vitamin D help MS?
It depends on what you mean by help. Observational studies link higher vitamin D levels to fewer relapses and fewer new lesions, but those are associations [3]. Randomized trials disagree: SOLAR and CHOLINE missed their primary endpoints, PrevANZ found no reduction in conversion to MS, and D-Lay MS found a lower composite disease activity score without a significant relapse difference [3][4][5]. Avoiding deficiency is the part most clinicians agree on.
How much vitamin D should I take with MS?
Start with a blood test, not a dose. For routine adult intake, the 2011 Institute of Medicine report sets 600 IU daily for ages 19 to 70 and 800 IU for ages 71 and older, with a 4,000 IU daily upper limit [6]. If you are deficient, a clinician may prescribe more and monitor you.
Is lipoic acid good for MS?
The 2026 phase 2 trial was null on walking speed at 1,200 mg daily for 24 months [10]. It showed imaging signals and more proteinuria, with a 37% versus 17% discontinuation rate. Lipoic acid is not proven to protect nerves. If you and your clinician decide to try it, 600 mg of R-lipoic acid was bioequivalent to 1,200 mg of the racemic form and had fewer GI side effects [11].
Does high-dose biotin help MS?
The pooled evidence says no for disability. A meta-analysis of 3 trials and 889 people found no significant EDSS benefit, a modest 25-foot walk-time signal, and lab test interference in 4.7% versus 0% [12]. The walk-time result is not strong enough to justify the safety risk without medical supervision.
What supplements should I avoid with MS?
Avoid anything marketed as an MS cure. Be cautious with immune-stimulating botanicals, high-dose biotin before blood tests, St John's wort with medications, and self-prescribed high-dose intermittent vitamin D [7][12]. Tell your neurologist about every supplement you take, including herbs and powders.
What helps MS fatigue?
The best-supported approaches are exercise, sleep, treating depression, and cognitive behavioral therapy. Supplements have weak evidence. CoQ10 at 500 mg daily showed a small signal in short, small studies [14][15], and adequate magnesium and folate intake showed a possible trend [17]. Start with the non-supplement basics.
Can supplements replace disease-modifying therapy?
No. Every trial in this guide tested supplements alongside standard care or in people not yet on therapy. None replaced it. Stopping or changing a DMT is a decision for your neurologist, and supplements are not a substitute.
References
- Walton C, King R, Rechtman L, et al. Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition. Mult Scler. 2020;26(14):1816-1821. https://pubmed.ncbi.nlm.nih.gov/33174475/
- Evans E, Piccio L, Cross AH. Use of Vitamins and Dietary Supplements by Patients With Multiple Sclerosis: A Review. JAMA Neurol. 2018;75(8):1013-1021. https://pubmed.ncbi.nlm.nih.gov/29710293/
- Smolders J, Torkildsen O, Camu W, Holmoy T. An Update on Vitamin D and Disease Activity in Multiple Sclerosis. CNS Drugs. 2019;33(12):1187-1199. https://pubmed.ncbi.nlm.nih.gov/31686407/
- Butzkueven H, Ponsonby AL, Stein MS, et al; PREVANZ Investigators. Vitamin D did not reduce multiple sclerosis disease activity after a clinically isolated syndrome. Brain. 2024;147(4):1206-1215. https://pubmed.ncbi.nlm.nih.gov/38085047/
- Thouvenot E, Laplaud D, Lebrun-Frenay C, et al; D-Lay MS Investigators. High-Dose Vitamin D in Clinically Isolated Syndrome Typical of Multiple Sclerosis: The D-Lay MS Randomized Clinical Trial. JAMA. 2025;333(16):1413-1422. https://pubmed.ncbi.nlm.nih.gov/40063041/
- Institute of Medicine Committee to Review Dietary Reference Intakes for Vitamin D and Calcium. Dietary Reference Intakes for Calcium and Vitamin D. Washington, DC: National Academies Press; 2011. https://pubmed.ncbi.nlm.nih.gov/21796828/
- Demay MB, Pittas AG, Bikle DD, et al. Vitamin D for the Prevention of Disease: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2024;109(8):1907-1947. https://pubmed.ncbi.nlm.nih.gov/38828931/
- Khalili M, Soltani M, Moghadam SA, Dehghan P, Azimi A, Abbaszadeh O. Effect of alpha-lipoic acid on asymmetric dimethylarginine and disability in multiple sclerosis patients: A randomized clinical trial. Electron Physician. 2017;9(7):4899-4905. https://pubmed.ncbi.nlm.nih.gov/28894553/
- Khalili M, Azimi A, Izadi V, et al. Does lipoic acid consumption affect the cytokine profile in multiple sclerosis patients: a double-blind, placebo-controlled, randomized clinical trial. Neuroimmunomodulation. 2014;21(6):291-296. https://pubmed.ncbi.nlm.nih.gov/24821457/
- Spain RI, Paz Soldan MM, Freedman MS, et al. Lipoic Acid for Treatment of Progressive Multiple Sclerosis: A Phase 2 Randomized Clinical Trial. Neurology. 2026;106(1):e214454. https://pubmed.ncbi.nlm.nih.gov/41397213/
- Cameron M, Taylor C, Lapidus J, Ramsey K, Koop D, Spain R. Gastrointestinal Tolerability and Absorption of R- Versus R,S-Lipoic Acid in Progressive Multiple Sclerosis: A Randomized Crossover Trial. J Clin Pharmacol. 2020;60(8):1099-1106. https://pubmed.ncbi.nlm.nih.gov/32212340/
- Espiritu AI, Remalante-Rayco PPM. High-dose biotin for multiple sclerosis: A systematic review and meta-analyses of randomized controlled trials. Mult Scler Relat Disord. 2021;55:103159. https://pubmed.ncbi.nlm.nih.gov/34332461/
- Sedighiyan M, Djafarian K, Dabiri S, Abdolahi M, Shab-Bidar S. The Effects of Omega-3 Supplementation on the Expanded Disability Status Scale and Inflammatory Cytokines in Multiple Sclerosis Patients: A Systematic Review and Meta-Analysis. CNS Neurol Disord Drug Targets. 2019;18(7):523-529. https://pubmed.ncbi.nlm.nih.gov/31096898/
- Salekzamani S, Pakkhesal S, Babaei M, et al. Coenzyme Q10 supplementation in multiple sclerosis; A systematic review. Mult Scler Relat Disord. 2025;93:106212. https://pubmed.ncbi.nlm.nih.gov/39667129/
- Moccia M, Capacchione A, Lanzillo R, et al. Coenzyme Q10 supplementation reduces peripheral oxidative stress and inflammation in interferon-beta1a-treated multiple sclerosis. Ther Adv Neurol Disord. 2019;12:1756286418819074. https://pubmed.ncbi.nlm.nih.gov/30815035/
- Cortese M, Chitnis T, Ascherio A, et al. Total intake of different minerals and the risk of multiple sclerosis. Neurology. 2019;92(18):e2127-e2135. https://pubmed.ncbi.nlm.nih.gov/30944237/
- Pommerich UM, Brincks J, Christensen ME. Is there an effect of dietary intake on MS-related fatigue? A systematic literature review. Mult Scler Relat Disord. 2018;25:282-291. https://pubmed.ncbi.nlm.nih.gov/30170268/
- Yi X, Zhang Y, Du Q, Kang J, Song Y, Li Y, Jiang Y. Global prevalence of fatigue in patients with multiple sclerosis: a systematic review and meta-analysis. Front Neurol. 2024;15:1457788. https://pubmed.ncbi.nlm.nih.gov/39416662/
- Oliva Ramirez A, Keenan A, Kalau O, et al. Prevalence and burden of multiple sclerosis-related fatigue: a systematic literature review. BMC Neurol. 2021;21(1):468. https://pubmed.ncbi.nlm.nih.gov/34856949/
- Shah VP, Nayfeh T, Alsawaf Y, et al. A Systematic Review Supporting the Endocrine Society Clinical Practice Guidelines on Vitamin D. J Clin Endocrinol Metab. 2024;109(8):1961-1974. https://pubmed.ncbi.nlm.nih.gov/38828942/
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
